Business Context and Reporting Period
This Form 8-K was filed by Artiva Biotherapeutics, Inc. on November 12, 2025. The report discloses positive initial safety and translational data from ongoing clinical trials of the investigational product AlloNK (AB-101) in combination with rituximab or obinutuzumab for the treatment of autoimmune diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures rather than financial performance.
Material Changes and Clinical Data
As of the data cutoff date of October 1, 2025, the following clinical milestones were reported:
- Patient Cohort: 32 patients treated across refractory rheumatoid arthritis (RA), Sjögren's disease, systemic sclerosis, and lupus nephritis in three ongoing Phase 1 and 2 trials.
- Safety Profile: The regimen was generally well tolerated. Most adverse events were Grade 1 or 2 and transient. No AlloNK-related Grade 3+ adverse events, serious adverse events, or discontinuations were reported. No cytokine release syndrome or Graft-versus-Host Disease occurred.
- Translational Data: All 23 patients with analyzed samples demonstrated non-quantifiable peripheral CD19+ B-cell levels by Day 13. B-cell reconstitution in four patients showed predominantly naïve and transitional cells.
- Administration: Treatment was administered in an outpatient setting at community rheumatology sites without specialized oncology oversight.
Guidance, Outlook, and Risks
Upcoming Milestones:
- Artiva plans to share initial clinical response data from more than 15 refractory RA patients in the first half of 2026.
- The company intends to conduct FDA regulatory interactions in the first half of 2026 to align on a potential pivotal trial design.
Management identifies an unmet need for over 150,000 patients in the United States who have failed at least two biologic or targeted synthetic disease modifying anti-rheumatic drugs.
Risks and Contingencies:The filing includes standard forward-looking statement disclaimers. AlloNK remains an investigational compound not approved by the FDA. Actual results may differ due to risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2025.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed safety data tables.
- Review the Company's most recent Form 10-Q (ended September 30, 2025) for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor the first half of 2026 for the release of clinical response data and the outcome of FDA regulatory interactions.
- Confirm the specific inclusion/exclusion criteria for the 32 patients treated to assess the generalizability of the safety data.